FUM vs. SCLP, OBI, MPH, HVO, ORPH, REDX, ETX, SBTX, COS, and C4XD
Should you be buying Futura Medical stock or one of its competitors? The main competitors of Futura Medical include Scancell (SCLP), Ondine Biomedical (OBI), Mereo BioPharma Group plc (MPH.L) (MPH), hVIVO (HVO), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry.
Futura Medical vs. Its Competitors
Futura Medical (LON:FUM) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.
Futura Medical has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Scancell has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.
35.7% of Futura Medical shares are owned by institutional investors. Comparatively, 46.5% of Scancell shares are owned by institutional investors. 32.1% of Futura Medical shares are owned by insiders. Comparatively, 5.0% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Futura Medical has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Futura Medical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Futura Medical and Futura Medical both had 1 articles in the media. Scancell's average media sentiment score of 0.59 beat Futura Medical's score of 0.00 indicating that Scancell is being referred to more favorably in the news media.
Scancell has a net margin of 0.00% compared to Futura Medical's net margin of -44.64%. Scancell's return on equity of 98.74% beat Futura Medical's return on equity.
Summary
Futura Medical beats Scancell on 6 of the 11 factors compared between the two stocks.
Get Futura Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for FUM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FUM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Futura Medical Competitors List
Related Companies and Tools
This page (LON:FUM) was last updated on 6/30/2025 by MarketBeat.com Staff
